The WGNV is an informal network of stakeholders engaged in all aspects of TB vaccine R&D and from all constituencies, including academics, product developers, clinicians, advocates, funders, policymakers, and affected communities. Membership is free and open to anyone who is supportive of the development of improved vaccines to prevent TB.
Members will be kept informed of new developments in TB vaccine research and
development, and will have an opportunity to participate on committees and subgroups
to advance WGNV activities and priorities.